Summary

There are several antiplatelet agents with diverse mechanisms of action that are or will be available for treatment of the growing population of patients with cardiovascular disease. The challenge will be to understand which patients may benefit from these therapies in combination with current treatment regimens and in the context of increasingly complex patients (eg, the elderly and diabetics).